Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
LONDON, June 18, 2013 /PRNewswire/ –
Edison Investment Research, a leading international investment research firm,
announces the initiation of full coverage of BioAlliance Pharma (BIO.PA), a French
biopharmaceutical company developing and marketing products for orphan oncology and
oncology supportive care indications.
Edison has today published a comprehensive report examining the investment merits of
BioAlliance Pharma, focusing in particular on the potential of its lead product, Livatag,
for hepatocellular carcinoma. Livatag is in a Phase III study, RELIVE, which is expected
to render final results in 2016. The report identifies a number of earlier catalysts,
including the potential partnering of Sitavig for cold sores, which was approved by the
FDA in April 2013. Edison has valued BioAlliance at EUR109m based on a risk-adjusted net
present value model.
For the full report see:
The launch of coverage on BioAlliance is part of a programme of research initiations
on healthcare companies worldwide. Edison provides research coverage on more than 130
healthcare companies in Europe, North America and Australia. Edison has pioneered a
scientific, detail-oriented approach to analysing companies in the healthcare sector that
is delivered in a concise and non-promotional manner. It aims to inform investors, while
providing a realistic assessment of the competitive strengths and threats to key drug
development programmes. All facts are carefully sourced and the analysis is underpinned by
comprehensive and rigorous financial models. Edison’s reports provide an overall company
valuation without any specific stock recommendation.
All reports published by Edison are available to download free of charge from its
About Edison Investment Research
Edison, the investment intelligence firm, is the future of investor interaction with
corporates. Our team of over 100 analysts and investment professionals works with leading
companies, fund managers and investment banks worldwide to support its capital markets
activity. We provide services to more than 400 retained corporate and investor clients
from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised
and regulated by the Financial Services Authority (
Edison is not an adviser or broker-dealer and does not provide investment advice.
Edison’s reports are not solicitations to buy or sell any securities.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting
and orphan products, BioAlliance conceives and develops innovative products for speciality
markets, especially in the hospital setting and for orphan or rare diseases. Created in
1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is
to become a leading player in these fields by coupling innovation with patient needs. The
company’s teams have the key competencies required to identify, develop and register drugs
in Europe and the USA.
For more information please contact: Luke Polonieki Edison Investment Research +44-(0)-20-3077-5700 firstname.lastname@example.org
SOURCE Edison Investment Research and BioAlliance Pharma